GANTANOL
LOE ApproachingNDAORALTABLET
Approved
Aug 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTANOL is a vintage oral tablet approved in 1965 by Roche, representing an early small-molecule therapeutic from the company's legacy portfolio. The generic name and specific mechanism of action are not publicly detailed in available records, indicating this is a mature, established product with historical significance in pharmaceutical development.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), suggesting a defensive or transition-focused team structure focused on managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GANTANOL presents limited direct career opportunities with zero linked jobs currently active. Working on this product offers experience in legacy brand management, generic transition strategy, and mature portfolio stewardship—valuable for understanding portfolio defense and market access in declining lifecycles.
Brand ManagerProduct Manager
Worked on GANTANOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.